Shona T. Dougherty, MB, ChB, PhD
Shona T. Dougherty, MB, ChB, PhD
Clinic Director
Contact Information
Background
Dr. Dougherty earned her medical degree from the University of Edinburgh, Edinburgh, Scotland in 1985, and her doctorate from the University of British Columbia, Vancouver, British Columbia, Canada in 1995. She was assistant professor at UCLA from 1996-2003, where she supervised the prostate seed brachytherapy program, as well as the TBI (total body irradiation) service. Dr. Dougherty joined the Arizona Cancer Center in August 2003, and has since been a zealous educator, directing the Radiation Oncology Residency Training Program since 2004.
Dr. Dougherty specializes in prostate cancer, and as an expert in prostate brachytherapy, presides over the prostate seed implant program at UAHN. Her primary interests include genitourinary cancers such as prostate, bladder and kidney disease. Additionally, she focuses on radiotherapy for gynecologic cancers, including various applications of brachytherapy. As a research scientist, Dr. Dougherty is currently involved in database construction to assess retrospective prostate radiotherapy outcomes. Dr. Dougherty became the departmental clinic director in 2003, and joined Dr. Baldassarre Stea (head of Radiation Oncology) as associate head of the department in 2008. She serves on several committees throughout the organization overseeing physician credentialing, resident education, quality assurance and program development.
-
AMA (American Medical Association)
-
BMA (British Medical Association)
-
AACR (American Association for Cancer Research)
-
ASTRO (American Society for Therapeutic Radiation Oncology)
-
CARO (Canadian Association for Radiation Oncology)
-
ABS (American Brachytherapy Society)
-
Distinction Award-Psychiatry, University of Edinburgh, Scotland
-
Distinction Award-Community Medicine, University of Edinburgh, Scotland
-
Selected to attend the Sixth National Cancer Institute of Canada Course in Oncology, McMaster University, Hamilton, Ontario, Canada
-
National Cancer Institute of Canada Fellowship Award
-
Canadian Association of Radiation Oncologists Residents Research Award (1992)
-
Canadian Association of Radiation Oncologists Residents Research Award (1993)
-
Listed in "The Best Doctors in America," 2009
Clinical
Board eligible for Radiation Oncology Fellow of the Royal College of Physicians and Surgeons of Canada USMLE I USMLE II LMCC (Licentiate of the Medical Council of Canada) CSA (Clinical Skills Assessment) ECFMG Certificate
Education
Research
Dougherty, G.J. and Dougherty, S.T. Exploiting the tumor microenvironment in the development of targeted cancer gene therapy. Cancer Gene Therapy 16(3) 279-290, 2009.
Dougherty, S.T. and Dougherty, G.J. Mechanisms conferring resistance to pro-apoptotic cancer gene therapy. Journal of Cell Death 4: 19-30, 2011.
Clinical Studies
Title | Description | Cancer Area | Cancer Type | Trial Status |
---|---|---|---|---|
NRG-GU007 |
NCT04037254: Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) |
|||
S1802 |
NCT03678025 Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer |
|||
Comppare |
NCT03561220 A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer |
|||
NRG-GU002 |
NCT03070886: Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant Docetaxel |
|||
1606636273 – NRG-GY006 |
NCT02466971 A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer |